Author

Paul Pollack 1

1 Eli Lilly and Company, Indianapolis, United States

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Fernando Magro, Gert De Hertogh, Marijana Protic, Lai Shan Chan, Paul Pollack, Brian G. Feagan, Noam Harpaz, Rish Pai, Walter Reinisch

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Geert R. D'Haens, Stefan Schreiber, Edouard Louis, Bruce E. Sands, Elisa Gomez Valderas, Debra Miller, Noah Agada, April Naegeli, Paul Pollack, Jochen Schmitz, Janneke van der Woude, Jaroslaw Kierkuś, William Sandborn

Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Geert R. D'Haens, Maria T. Abreu, Ruth Belin, Elisa Gomez Valderas, Debra Miller, April Naegeli, Vipin Arora, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY OF USTEKINUMAB FOR INDUCTION AND MAINTENANCE OF ENDOSCOPIC HEALING IN PATIENTS WITH CROHN?S DISEASE

Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B Hanauer, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Brian G. Feagan, William Sandborn

EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB

William Sandborn, Bruce E. Sands, Pieter Hindryckx, Monika Fischer, Kim Isaacs, April Naegeli, Debra Miller, Elisa Gomez Valderas, Noah Agada, Paul Pollack, Geert R. D'Haens

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Rish Pai, Gert De Hertogh, Walter Reinisch, Noam Harpaz, Brian Feagan, Noah Agada, Paul Pollack, Lai Shan Chan, Marijana Protic, Fernando Magro

Impact of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores in Patients with Moderate to Severely Active Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Miguel Reguiero, Monika Fischer, David T. Rubin, Toshifumi Hibi, Peter Bossuyt, Pascal Juillerat, Paul Pollack, Xian Zhou, Marijana Protic, Theresa Hunter Gibble, Lai Shan Chan, Hilde Carlier, Pieter Hindryckx

Item 1 - 10 / 21
1
2 3